Market Place
Sourcing Support
Theriva Biologics Announces Reverse Stock Split
16 Aug 2024 //
GLOBENEWSWIRE
Theriva to Participate in the B. Riley Securities Annual Oncology Conference
16 Jan 2024 //
GLOBENEWSWIRE
Theriva Biologics to Participate in Upcoming Investor Conferences
01 Dec 2022 //
GLOBENEWSWIRE
Theriva Biologics Reports 3Q 2022 Operational Highlights and Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Theriva to Reschedule Conference Call to Discuss 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Theriva Announces First Patient Dosed in Phase 1b/2a Trial of SYN-004
03 Nov 2022 //
GLOBENEWSWIRE
Theriva Biologics to Host Conference Call and Webcast to Discuss 3Q 2022
03 Nov 2022 //
GLOBENEWSWIRE
Synthetic Biologics rebrands as Theriva Biologics
13 Oct 2022 //
PHARMABIZ
Synthetic completes transformation with new name and cancer-killing virus focus
12 Oct 2022 //
ENDPTS
Synthetic Biologics Announces Presentation at SIOP International Society
30 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces +ve Outcome of (DSMC) Review in Ph1b/2a SYN-004
27 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Ph1
05 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Discuss Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
04 Aug 2022 //
GLOBENEWSWIRE
Synthetic Bio Announces $3M Private Placement of Convertible Preferred Stock
29 Jul 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Reverse Stock Split
15 Jul 2022 //
GLOBENEWSWIRE
Synthetic Biologics Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Discuss First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Formation of Scientific Advisory Board
05 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Presentation on VCN-11 at ASGCT
04 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Publish Phase 1 Trial of i.v VCN-01 Oncolytic Adenovirus
28 Mar 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Management Transitions
23 Mar 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference
22 Mar 2022 //
GLOBENEWSWIRE
Synthetic Biologics Reports 2021 Year End Financial Results
16 Mar 2022 //
GLOBENEWSWIRE
Synthetic Biologics acquires VCN Biosciences
14 Mar 2022 //
PHARMABIZ
Synthetic Biologics Completes Acquisition of VCN Biosciences
11 Mar 2022 //
GLOBENEWSWIRE
Synthetic Bio to Discuss 2021 Year End Operational Highlight, Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Synthetic Biologics plans transformative acquisition of VCN Biosciences
16 Dec 2021 //
PHARMABIZ
Synthetic Biologics Announces Planned Transformative Acquisition VCN Biosciences
14 Dec 2021 //
GRIFOLS
Synthetic Biologics Reports Q3 2021 Operational Highlights and Financial Results
03 Nov 2021 //
PRNEWSWIRE
Synthetic Biologics begins patient dosing in phase 1 clinical trial for SYN-020
22 Oct 2021 //
PHARMABIZ
Synthetic Biologics Announces Initiation of a Phase 1Trial for SYN-020
21 Oct 2021 //
PRNEWSWIRE
Synthetic Biologics Expands Option for an Exclusive License Agreement
03 Aug 2021 //
PRNEWSWIRE
Synthetic Biologics Provides Update on SYN-020
29 Jun 2021 //
PRNEWSWIRE
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase
29 Jun 2021 //
PR NEWSWIRE
Synthetic Announces First Patient Dosed in Phase 1b/2a Trial of SYN-004
14 Apr 2021 //
PRNEWSWIRE
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical
01 Apr 2021 //
PRNEWSWIRE
Synthetic Biologics Announces Washington University School of Medicine
22 Dec 2020 //
PRNEWSWIRE
Synthetic Biologics Announces Washington University School of Medicine
22 Dec 2020 //
PRNEWSWIRE
Synthetic Biologics Announces Washington USM in St. Louis IRB
22 Dec 2020 //
PRNEWSWIRE
Synthetic Announces Washington University School of Medicine in St. Louis IRB
22 Dec 2020 //
PRNEWSWIRE
Synthetic Biologics cans phase 2 IBS trial deemed likely to fail
02 Oct 2020 //
FIERCE BIOTECH
Synthetic Biologics receives US FDA clearance to begin phase 1 study of SYN-020
30 Jul 2020 //
PHARMABIZ
Synthetic Biologics Announces FDA Clearance of iNDA for SYN-020 (IAP)
30 Jul 2020 //
PRNEWSWIRE
Synthetic Biologics seeks US FDA approval to initiate phase 1 study of SYN-020
02 Jul 2020 //
PHARMABIZ
Synthetic Biologics inks pact with MGH to license IP for use of SYN-020
29 May 2020 //
PHARMABIZ
Synthetic Biologics Enters into Exclusive Option to License IP for of SYN-020
27 May 2020 //
PRNEWSWIRE
